Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Bullboard (TSXV:ARCH)

View:
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
Comment by wethenorthhon Dec 02, 2021 10:26pm

RE:My thoughts exactly

hahahahaha! I'm getting ready to hand out these apology forms to all the haters :) 
77
Discussion
Post by SrPlataon Dec 02, 2021 9:15pm

Open Label and WHO Solidarity Trials Trump Phase 3

  What the market is missing on the latest announcement. The key is Open Label and the WHO Solidartiy Trials. Let me explain, because CATCO is in charge and is an advocate for LSALT for Lungs ...more  
167
Post by Riverfolkon Dec 02, 2021 7:14pm

$5.00- Extremely Undervalued in Comparison to Phase II peers

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our Phase II peer group . REMEMBER THAT WE ARE NOW A ...more  
131
Post by Riverfolkon Dec 02, 2021 7:03pm

Todays House Positions

House Positions for C:ARCH from 20211202 to 20211202 House Bought $Val Ave Sold $Val Ave Net $Net ...more  
108
Post by Riverfolkon Dec 02, 2021 3:39pm

Minister of Innovation, Science and Industry

https://twitter.com/FP_Champagne/status/1466445214671949824?s=20 Canadian innovators are playing a key role in the global race for COVID-19 treatments. Congratulations to @Archbiopartners for ...more  
112
Post by 2019champson Dec 02, 2021 2:36pm

We used to trade 5-10k shares a day

Remember guys, this stock was trading really low volume. Alot of days i remember seeing 5-10k volume, and this wasn't long ago. Our average volume now is about 70k. The awareness is growing slowly ...more  
128
Post by Riverfolkon Dec 02, 2021 2:02pm

Probability of Success - 52.8% ( 20 Billion unmet Market)

New Clinical Developement Succes Rates 2011-2020 Report Statistically speaking in the report available above, Arch Biopartners has a 52.8% chance of having a drug make it ot the approval process from ...more  
165
Comment by fourbarrelson Dec 02, 2021 1:39pm

RE:RE:RE:RE:RE:RE:Calgary herald

My understanding is this will cost the government $30k per patient so $9 to $10 million for the Covid application trial. Lovely!!
70
Discussion
Comment by Riverfolkon Dec 02, 2021 1:36pm

RE:RE:RE:RE:RE:RE:Calgary herald

The Market is being extremely inefficient, I cant argue that at all. Just as it was when the governement funding for phase II was announced. The biosciences Sector is extremely difficult to understand ...more  
85
Discussion
Comment by wethenorthhon Dec 02, 2021 1:27pm

RE:Arch Biopartners - My Due Diligence (NEW)

Thanks Riverfolk, certainly super helpful DD.  Market will understand at some point how big this drug is and start chasing as this company keeps overachieving.  No dilution for a phase 3 ...more  
72
Discussion
Comment by GoldenArmon Dec 02, 2021 1:16pm

RE:RE:RE:RE:RE:Calgary herald

The market is in a bad mood lately but the companies results are very good such that a bigger human trial is needed. 55,000 shares traded so far today isn't a hell of a lot of shares. It tells me ...more  
72
Discussion
Comment by Arbourmarkon Dec 02, 2021 1:04pm

RE:RE:RE:RE:Calgary herald

I am happy that is your interpretation but I respectfully state the market has a different view at this time and needs clarity. If the markets agreed with your comments below and based on numerous ...more  
69
Discussion
Comment by GoldenArmon Dec 02, 2021 12:50pm

RE:CONGRATULATIONS EVERYONE - THIS WORKED IN A HUMAN!!

Yes that is what I got out of it. If you are on a ventilator and you get this drug you recover faster. The next trial in my opinion is equal to Phase 3 trial in US. With the backing of the WHO and ...more  
75
Discussion
Prev ... 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities